News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,623 Results
Type
Article (53108)
Company Profile (488)
Press Release (691027)
Section
Business (216778)
Career Advice (2848)
Deals (37231)
Drug Delivery (113)
Drug Development (86607)
Employer Resources (180)
FDA (17054)
Job Trends (15871)
News (367935)
Policy (35484)
Tag
Academia (2896)
Alliances (52910)
Alzheimer's disease (1346)
Approvals (16968)
Artificial intelligence (162)
Bankruptcy (379)
Best Places to Work (12225)
Biotechnology (363)
Breast cancer (197)
Cancer (1403)
Cardiovascular disease (120)
Career advice (2382)
Cell therapy (298)
Clinical research (68865)
Collaboration (478)
Compensation (253)
COVID-19 (2759)
C-suite (118)
Data (1393)
Diabetes (177)
Diagnostics (6527)
Drug pricing (103)
Earnings (87559)
Employer resources (157)
Events (118223)
Executive appointments (381)
FDA (17707)
Funding (433)
Gene therapy (217)
GLP-1 (685)
Government (4789)
Healthcare (20063)
Infectious disease (2852)
Inflammatory bowel disease (123)
Interviews (551)
IPO (16954)
Job creations (4074)
Job search strategy (1974)
Layoffs (471)
Legal (8682)
Lung cancer (203)
Manufacturing (211)
Medical device (13899)
Medtech (13904)
Mergers & acquisitions (20386)
Metabolic disorders (486)
Neuroscience (1690)
NextGen Class of 2024 (7221)
Non-profit (4904)
Northern California (1676)
Obesity (281)
Opinion (229)
Patents (122)
People (61385)
Phase I (21422)
Phase II (30220)
Phase III (22557)
Pipeline (515)
Postmarket research (2929)
Preclinical (9239)
Radiopharmaceuticals (254)
Rare diseases (278)
Real estate (6412)
Regulatory (23520)
Research institute (2572)
Resumes & cover letters (456)
Southern California (1462)
Startups (3899)
United States (15483)
Vaccines (631)
Weight loss (215)
Date
Today (78)
Last 7 days (707)
Last 30 days (2851)
Last 365 days (37217)
2024 (36302)
2023 (41910)
2022 (53245)
2021 (57910)
2020 (56653)
2019 (49893)
2018 (37736)
2017 (34717)
2016 (34539)
2015 (40639)
2014 (34676)
2013 (29991)
2012 (32010)
2011 (32485)
2010 (30743)
Location
Africa (909)
Arizona (209)
Asia (42229)
Australia (7642)
California (3835)
Canada (1429)
China (300)
Colorado (173)
Connecticut (184)
Europe (94221)
Florida (528)
Georgia (133)
Illinois (412)
Indiana (227)
Maryland (651)
Massachusetts (3041)
Michigan (177)
Minnesota (300)
New Jersey (1097)
New York (1077)
North Carolina (839)
Northern California (1676)
Ohio (148)
Pennsylvania (918)
South America (1288)
Southern California (1462)
Texas (552)
Utah (110)
Washington State (412)
744,623 Results for "c3j therapeutics formerly known as c3 jian inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2024
December 4, 2024
·
1 min read
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Policy
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.
June 20, 2024
·
2 min read
Press Releases
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 9, 2024
·
12 min read
Press Releases
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
October 28, 2024
·
16 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Genetown
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Akebia Therapeutics today announced that John Butler , Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024.
June 27, 2024
·
1 min read
Press Releases
StimCell Energetics Inc. (Formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding
November 4, 2024
·
3 min read
Press Releases
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 3, 2024
December 4, 2024
·
1 min read
1 of 74,463
Next
